Verastem, Inc. (VSTM) ended last trading session with a change of 24.19 percent. It trades at an average volume of 160.83K shares versus 2.48M shares recorded at the end of last trading session. The share price of $1.54 is at a distance of 46.67 percent from its 52-week low and down -20.21 percent versus its peak. The company has a market cap of $57.38M and currently has 37.26M shares outstanding. The share price is currently 28.12 percent versus its SMA20, 28.08 percent versus its SMA50, and 19.45 percent versus its SMA200. The stock has a weekly performance of 30.51 percent and is 37.5 percent year-to-date as of the recent close.
On January 26, 2017 Verastem, Inc., (VSTM) announced dosing of the first patient in a new clinical trial evaluating avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in combination with Verastem’s defactinib, an investigational focal adhesion kinase (FAK) inhibitor, in patients with advanced ovarian cancer. The Phase 1/2 clinical trial is being conducted in collaboration with the alliance between Merck KGaA, Darmstadt, Germany, which in the US and Canada operates as EMD Serono, and Pfizer, and is expected to enroll approximately 100 patients at up to 15 sites across the U.S.
Cara Therapeutics, Inc. (CARA) recently recorded -3.22 percent change and currently at $15.33 is 252.41 percent away from its 52-week low and down -21.14 percent versus its peak. It has a past 5-day performance of -14.45 percent and trades at an average volume of 1.69M shares. The stock has a 1-month performance of -6.12 percent and is 65.02 percent year-to-date as of the recent close. There were about 30.13M shares outstanding which made its market cap $461.89M. The share price is currently -3.09 percent versus its SMA20, 10.12 percent versus its SMA50, and 74.35 percent versus its SMA200.
On March 13, 2017 Cara Therapeutics, Inc. (CARA) announced that it will present at two upcoming medical meetings.
At the American Academy of Orthopaedic Surgeons (AAOS) 2017 Annual Meeting (to be held March 14-18, 2017 in San Diego), Dr. Joseph Stauffer, Cara’s Chief Medical Officer, will moderate a satellite symposium discussing kappa opioid receptor agonists (KORAs) as a novel approach to acute and chronic pain management. This discussion will highlight clinical trial data for CR845, the Company’s first-in-class peripherally selective kappa opioid agonist. To date, results support the view that CR845 is unlikely to be recreationally abused or lead to physical dependence.